Bill_ENG, maybe not full B/O, you're right. Read this from SA:
"There are two main possibilities. One, leronlimab could be licensed to a big pharma that doesn’t have any ownership of a CCR5 inhibitor. Second, leronlimab could be licensed to a big pharma company that has a CCR5 inhibitor and the knowledge about how they work, but wants access to a CCR5 inhibitor with a better pharmacokinetic (PK) and tolerability profile, i.e., leronlimab.
Big pharmas that have CCR5 inhibitors are the aforementioned AbbVie, Pfizer (PFE), which owns maraviroc, and Merck (MRK), which owns vicriviroc. Vicriviroc’s development was discontinued over a decade ago based on HIV results. All of these drugs are small molecules with inferior tolerability and PK profiles. None of them seem to work as well in HIV because of the inferior PK profile, likely inferior receptor occupancy (all receptors need to be blocked to stop HIV infection of new cells), and the fact that HIV might still somehow mutate and bind to CCR5 when it is not being blocked by a larger antibody such as leronlimab.
Either way, these companies might have an interest in getting a head start in COVID-19 treatment with a better CCR5 inhibitor, and leronlimab is their only avenue to do so."
IMO, PFE is the best partner,suitor,buyer for CYDY. Previously I posted they are flush with vaccine cash . Coincidentally they are HQ'ed in NYC and the board/CYDY team are heading there next week. Why not just ZOOM the meeting online? I think things need to be done 'in person'. (theory).
Lets see what happens. Exciting times ahead, regardless and LIVES need to be SAVED.
GLTU/A.
